Cancer Immunotherapy Gets a Power Up by PIP

Researchers at Kyoto University report they have developed a synthetic molecule called pyrrole-imidazole polyamide (PIP), that can be programmed to target a specific DNA sequence, and provide energy to anticancer immune cells. Further improvements are needed before the approach can be tested for clinical use, but the new approach gives hope to overcoming some of the limitations of immunotherapy.